Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A12352 | Pages: NA | Charts: NA | Tables: NA |
Pizotifen is a class of benzocycloheptene, which is commonly sold under name Sandomigran. Pizotifen is primarily used in prevention and to reduce frequency of migraine and cluster headaches. It is effective and its use is limited by side effects such as drowsiness and weight gain. It is seen to be effective in treatment of severe cases of erythromelalgia, a rare neurological disease. Patients with kidney dysfunction, history of epilepsy, and symptoms such as depression are not advised to take pizotifen drug.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the pizotifen market.
Top Impacting Factors
Market Trend
Rise in R&D Activities to Develop Novel Pizotifen Product
In 2021, an article was published on pizotifen. The article states that HTR2C inhibitor drug pizotifen acts as a suppressor of EMT-mediated metastasis.
In 2019, new report was discovered that Pizotifen represses the practicality of gastric malignancy MNK45 and AGS cells. A CCK8 test was done to decide the impact of pizotifen on the suitability of gastric disease cell lines MNK45 and AGS.
Surge in Migraine and Cluster Headache Treatment Procedures
Increase in cases of migraine & cluster headaches, increase in medical facility services in rural areas, and surge in demand for rapid pain relief drugs drive the growth of pizotifen market. As per the data of Migraine Research Foundation, roughly 39 million people in the U.S. are suffering from migraine and 1 billion people around the globe have migraine. This makes migraine as a third most common disorder in world. In addition, surge in health care expenditure, agreements, takeovers, joint ventures, & geographical expansions by key players in the market to increase R&D activities to improve quality of drugs, launch of novel drugs in market, and technological development are some factors that augment the market growth.
Key Benefits of the Report
Questions Answered in the Pizotifen Market Report
Key Market Segments
Key Market Players